Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H1 2018

  • ID: 4540594
  • Report
  • 102 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Clevexel Pharma SAS
  • Japan Tobacco Inc
  • KBP BioSciences Co Ltd
  • MORE
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2018'; Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 24 molecules. Out of which approximately 24 molecules are developed by Companies.

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.

The report 'Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2018' outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 4, 2, 10 and 4 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders and Ophthalmology which include indications Rheumatoid Arthritis, Alopecia, Psoriasis, Atopic Dermatitis, Ulcerative Colitis, Vitiligo, Crohn's Disease (Regional Enteritis), Diffuse Large B-Cell Lymphoma, Inflammation, Mantle Cell Lymphoma, Allergic Conjunctivitis, Androgenic Alopecia, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Autoimmune Disorders, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cachexia, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Cutaneous T-Cell Lymphoma, Dermatomyositis, Eczema, Follicular Lymphoma, Heart Transplant Rejection, Inflammatory Bowel Disease, Juvenile Rheumatoid Arthritis, Marginal Zone B-cell Lymphoma, Myeloproliferative Disorders, Peripheral T-Cell Lymphomas (PTCL), Pruritus, Psoriatic Arthritis, Sarcopenia, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) and Waldenstrom Macroglobulinemia.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Clevexel Pharma SAS
  • Japan Tobacco Inc
  • KBP BioSciences Co Ltd
  • MORE
Introduction

Report Coverage

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Bristol-Myers Squibb Co

Chipscreen Biosciences Ltd

Clevexel Pharma SAS

Guangdong Zhongsheng Pharmaceutical Co Ltd

Japan Tobacco Inc

KBP BioSciences Co Ltd

LSK BioPartners Inc

Merck & Co Inc

MYOS RENS Technology Inc

Pfizer Inc

Portola Pharmaceuticals Inc

Sienna Biopharmaceuticals Inc

Simcere Pharmaceutical Group

Theravance Biopharma Inc

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles

ARN-4079 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-510 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0074 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delgocitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-7536 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSK-9985 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OST-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OST-246 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peficitinib hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06651600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK1 and JAK3 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Apr 25, 2018: Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2018: Aclaris Therapeutics Announces First Patient Dosed in a Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia

Mar 12, 2018: Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitis

Mar 08, 2018: Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ (tofacitinib) for Moderately to Severely Active Ulcerative Colitis

Feb 14, 2018: Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-

Feb 12, 2018: Xeljanz is accepted for restricted use within NHS Scotland

Feb 08, 2018: Astellas Announce Top-Line Results for Two Phase 3 Trials of Peficitinib in Rheumatoid Arthritis Patients with Inadequate Response to Existing Therapy

Jan 12, 2018: Top-line Results of the Topical JTE-052 JAK Inhibitor Phase 3 Clinical Study (Comparative Study) in Japan

Dec 19, 2017: Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo

Dec 14, 2017: Pfizer Announces FDA Approval Of Xeljanz (Tofacitinib) For The Treatment Of Active Psoriatic Arthritis

Dec 14, 2017: Pfizer Announces FDA Approval Of Xeljanz XR For The Treatment Of Active Psoriatic Arthritis

Dec 12, 2017: U.S. Food And Drug Administration Extends Action Date For XELJANZ (Tofacitinib) Supplemental New Drug Application In Ulcerative Colitis By Three Months

Nov 30, 2017: Portola Pharmaceuticals to Present New Data on Cerdulatinib at the 59th American Society of Hematology (ASH) Annual Meeting

Oct 16, 2017: New Ulcerative Colitis Data for XELJANZ (tofacitinib)at Upcoming Gastroenterology Congresses

Sep 08, 2017: NICE issues positive recommendation for XELJANZ (tofacitinib citrate) as a new treatment option for adults with severe rheumatoid arthritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Aclaris Therapeutics Inc, H1 2018

Pipeline by Arrien Pharmaceuticals LLC, H1 2018

Pipeline by Astellas Pharma Inc, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by Chipscreen Biosciences Ltd, H1 2018

Pipeline by Clevexel Pharma SAS, H1 2018

Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2018

Pipeline by Japan Tobacco Inc, H1 2018

Pipeline by KBP BioSciences Co Ltd, H1 2018

Pipeline by LSK BioPartners Inc, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Pipeline by MYOS RENS Technology Inc, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Portola Pharmaceuticals Inc, H1 2018

Pipeline by Sienna Biopharmaceuticals Inc, H1 2018

Pipeline by Simcere Pharmaceutical Group, H1 2018

Pipeline by Theravance Biopharma Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Aclaris Therapeutics Inc
  • Arrien Pharmaceuticals LLC
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Chipscreen Biosciences Ltd
  • Clevexel Pharma SAS
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Japan Tobacco Inc
  • KBP BioSciences Co Ltd
  • LSK BioPartners Inc
  • Merck & Co Inc
  • MYOS RENS Technology Inc
  • Pfizer Inc
  • Portola Pharmaceuticals Inc
  • Sienna Biopharmaceuticals Inc
  • Simcere Pharmaceutical Group
  • Theravance Biopharma Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll